SLASKIE CENTRUM CHOROB SERCA W ZABRZU

Their core work

Slaskie Centrum Chorob Serca w Zabrzu (Silesian Center for Heart Diseases in Zabrze) is a specialized cardiac clinical center in southern Poland that performs complex cardiovascular surgeries and manages heart disease patients. Their EU research participation reflects a clinical trial role: they contribute real-world surgical expertise, patient cohorts, and procedural knowledge to multi-center studies. In the PAPA-ARTIS trial, they brought direct operative experience in thoracoabdominal aortic aneurysm repair — one of the highest-risk procedures in vascular surgery — and in spinal cord protection protocols designed to prevent post-operative paraplegia. Earlier involvement in FRESHER positioned them as a data-contributing clinical site for European health policy modeling.

What they specialise in

How they've shifted over time

Their first H2020 project (FRESHER, 2015–2017) carried no specific clinical keywords, suggesting a broad, data-contributor role in a health policy and regulatory foresight study — useful for establishing EU research presence but not reflective of their core surgical identity. By 2017, with PAPA-ARTIS, the focus sharpened entirely onto the procedural specifics of aortic surgery: aneurysm repair technique, staged intervention, and intraoperative neuroprotection. The seven-year duration of PAPA-ARTIS (through 2024) reinforces that this is not an incidental topic — it maps directly onto the advanced vascular surgery capabilities a major cardiac center like SCCS is built around.

SCCS is consolidating around high-stakes cardiovascular surgical research, particularly complex aortic procedures and neuroprotection — a niche where specialist clinical centers with real operative volume are scarce and valuable in European consortia.

How they like to work

SCCS has never led an H2020 project — both participations were as a consortium partner, which is typical for clinical centers whose value lies in patient access and surgical expertise rather than project management. Despite only two projects, they connected with 44 unique partners across 15 countries, indicating they joined large, well-networked multi-site trials rather than small bilateral collaborations. This pattern suggests they are sought out as a clinical execution site, not as a research initiator.

With 44 consortium partners across 15 countries from only two projects, SCCS has a surprisingly broad European footprint — a direct consequence of joining large multi-center RCTs and pan-European foresight consortia. Their network skews toward academic medical centers and health research institutions across Western and Central Europe.

What sets them apart

SCCS is one of the few Polish cardiac surgery centers with documented participation in EU-funded randomized clinical trials for complex aortic procedures — a domain where active surgical volume is the primary qualification and few centers qualify. Located in Zabrze, an industrial city in the Silesian region with a historically high cardiovascular disease burden, they have both the patient population and the operational depth to serve as a credible clinical site. For any consortium needing a Central/Eastern European surgical partner in vascular or cardiac RCTs, SCCS fills a role that general hospitals cannot.

Highlights from their portfolio

• PAPA-ARTIS
  A seven-year randomized controlled trial (2017–2024) targeting one of the most technically demanding procedures in vascular surgery, making it the defining project for SCCS's EU research identity and their largest single funding award (EUR 119,910).
• FRESHER
  Demonstrated early appetite for pan-European health research beyond their surgical specialty, connecting SCCS to a 44-partner network and signaling openness to multi-disciplinary health policy work.